New combo therapy shows promise for bile duct cancer
NCT ID NCT05052099
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 25 times
Summary
This study tested a combination of three drugs (mFOLFOX6, bevacizumab, and atezolizumab) in 20 people with advanced bile duct cancer who had already tried one prior treatment. The goal was to see if this combination could shrink tumors or slow the disease. The drugs were given every two weeks until the cancer worsened, side effects became too severe, or the patient chose to stop.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Clínica Universidad de Navarra
Pamplona, 31008, Spain
-
Universitätsklinikum Essen
Essen, North Rhine-Westphalia, 45147, Germany
Conditions
Explore the condition pages connected to this study.